Guidant Launches Cobalt Chromium Coronary Stent System in Japan; MULTI-LINK VISION(R) RX Coronary Stent System Provides Thin Str
06 Octobre 2005 - 9:39PM
Business Wire
Guidant Corporation (NYSE:GDT) today announced that the company has
launched the MULTI-LINK VISION(R) RX Coronary Stent System in
Japan, following regulatory and reimbursement approvals. The
rapid-exchange MULTI-LINK VISION RX Stent System is part of
Guidant's innovative class of cobalt chromium stents. Cobalt
chromium is stronger and more radiopaque than stainless steel,
giving cobalt chromium stents thinner struts without compromising
visibility. The result is a lower profile and more deliverable
stent that enables physicians to access challenging coronary
lesions. "The MULTI-LINK VISION RX Stent System integrates the
features of a cobalt chromium stent with Guidant's rapid-exchange
delivery system. With its thin struts and superb deliverability,
the VISION RX Stent System has consistently demonstrated excellent
acute performance and long-term clinical outcomes," said John M.
Capek, Ph.D. president, Vascular Intervention, Guidant Corporation.
"We are pleased that regulatory and reimbursement approvals have
taken place rapidly, allowing us to provide this important
technology to patients in Japan." Japan's Ministry of Health,
Labour and Welfare (MHLW) approved the MULTI-LINK VISION RX
Coronary Stent System in 3.0 mm to 4.0 mm diameters and 8 mm to 28
mm lengths in coronary vessels. The MULTI-LINK VISION Registry has
demonstrated positive clinical results with 1.9 percent clinically
driven target lesion revascularization and a 15.7 percent binary
restenosis rate at six months. "The MULTI-LINK VISION RX offers
excellent clinical results for the treatment of coronary artery
disease," said Greg Davis, president, Guidant, Japan K.K. "This
breakthrough cobalt chromium stent is a welcome new option for
physicians in Japan." Guidant plans to use its cobalt chromium
stent technology in future drug eluting stent programs. The company
recently initiated SPIRIT II AND SPIRIT III, large-scale pivotal
clinical trials evaluating the safety and efficacy of Guidant's
drug eluting stent system for the treatment of coronary artery
disease. These prospective, randomized, single-blind trials compare
XIENCE(TM) V, an everolimus eluting stent system utilizing
Guidant's cobalt chromium MULTI-LINK VISION(R) Coronary Stent
System platform, versus the TAXUS(R) Express 2(TM) Paclitaxel
Eluting Coronary Stent System. Guidant received Clinical Trial
Notification acceptance from the MHLW in September to begin patient
enrollment in the SPIRIT III Japan Registry. Guidant offers a broad
family of stents designed to meet needs of customers in Japan. In
July 2004, the company launched its fifth-generation stainless
steel stent in Japan, the MULTI-LINK ZETA(R) Coronary Stent System.
Guidant's MULTI-LINK PIXEL(R) Coronary Stent System, launched in
Japan earlier this year, is designed specifically for small vessels
in patients presenting with abrupt or threatened abrupt closure.
Guidant Corporation pioneers lifesaving technology, giving an
opportunity for better life today to millions of cardiac and
vascular patients worldwide. The company, driven by a strong
entrepreneurial culture of 12,000 employees, develops, manufactures
and markets a broad array of products and services that enable less
invasive care for some of life's most threatening medical
conditions. For more information visit www.guidant.com. NOTE TO
MEDIA: For more information about Guidant, including its products
and services, please visit the company's newsroom at
www.guidant.com/newsroom.
Guidant (NYSE:GDT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Guidant (NYSE:GDT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Guidant Corp (New York Stock Exchange): 0 recent articles
Plus d'articles sur Guidant Corporation